Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Rifaximin · Xifaxan, NSC-758957

Small molecule · Inhibitor of Escherichia coli · developed by Salix Pharms

Approved FDA, May 2004

BHC Developer

3 Registered trials

What is Rifaximin?

Rifaximin is a rifamycin antibacterial agent indicated for treating travelers' diarrhea caused by noninvasive Escherichia coli, reducing hepatic encephalopathy recurrence, and treating irritable bowel syndrome with diarrhea in adults and pediatric patients 12 years and older.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Xifaxan, NSC-758957
Drug type: Small molecule
Targets: Escherichia coli
Mechanism: Inhibitor of Escherichia coli
Therapy area: Gastroenterology, Infectious disease
Developer: Salix Pharms (BHC)
FDA status: Approved as Xifaxan (May 25, 2004), NDA021361 · FDA label
UNII: L36O5T016N

✅ FDA-approved uses

Travelers' diarrhea caused by noninvasive strains of Escherichia coli
Reduction in risk of overt hepatic encephalopathy recurrence
Irritable bowel syndrome with diarrhea

From the indications section of the FDA label (version of Aug 27, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07285785	Phase 4	Diarrhea	Recruiting	BHC
NCT06312683	Phase 4	Pouchitis	Recruiting	BHC
NCT06718686	Phase 1/2	Dementia Alzheimer Type	Recruiting	BHC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute DiarrheaBacterial InfectionDementia Alzheimer TypeDementia Associated With Cerebrovascular DiseaseDiarrheaGastroenteritisPouchitis

More from Salix Pharms

Adapalene / Benzoyl Peroxide / Clindamycin FDA approved Brodalumab FDA approved Bupropion FDA approved Halobetasol Propionate And Tazarotene FDA approved IDP-118 FDA approved IDP-126 FDA approved Lifitegrast FDA approved Perfluorohexyloctane FDA approved Plecanatide FDA approved Timolol FDA approved BL1107 Phase 2 BL1332 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHC page.

Follow BHC, the company behind Rifaximin

See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z